Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) serves as a notification to the U.S. Securities and Exchange Commission regarding the upcoming announcement of full-year and fourth-quarter 2021 financial results. The filing was submitted on February 7, 2022, for the month of February 2022.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice announcing the timing of the results release rather than a financial statement containing performance data.
Material Changes
No material changes to financial performance are detailed in this filing, as the actual results for the period have not yet been disclosed in this text.
Guidance, Outlook, and Management Commentary
GSK announced that full-year and fourth-quarter 2021 results will be released to the London Stock Exchange at 07:00 GMT on Wednesday, February 9, 2022. A conference call and webcast, including a presentation and Q&A session, are scheduled for 14:00 GMT on the same day. The presentation materials will be available on the company website approximately one hour prior to the event.
Investor Verification Checklist
- Verify the actual financial results released on February 9, 2022, as this filing contains no numerical data.
- Confirm the timing of the conference call and webcast for the Q4 and full-year 2021 results.
- Review the presentation materials posted on the GSK website prior to the event start time.